Trials / Completed
CompletedNCT05245032
Biologically Focused Therapy of Treatment-Refractory MDS Patients
Biologically Focused Therapy of Treatment Refractory MDS Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.
Detailed description
This study utilizes the Notable Labs personalized testing service using an ex vivo assay, but does not involve actual treatment or treatment determinations. The results of these screenings will be made available to patients and their physicians for their use off study. The primary objective of the study is: • To determine the feasibility of selecting patient specific treatment regimens based on ex vivo within 30 days The exploratory objectives of the study are: • To identify biomarkers that explain ex vivo drug sensitivity results
Conditions
Timeline
- Start date
- 2020-02-18
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2022-02-17
- Last updated
- 2025-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05245032. Inclusion in this directory is not an endorsement.